length human lrp6 coding sequence (Addgene inc)
Structured Review

Length Human Lrp6 Coding Sequence, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/full+length+human+lrp6+coding+sequence/LRP6-pCS2-VSVG+(Plasmid+%2327282)/pm33391533-33-1-10
Average 93 stars, based on 5 article reviews
Images
1) Product Images from "Low-density lipoprotein receptor-related protein 6 regulates cardiomyocyte-derived paracrine signaling to ameliorate cardiac fibrosis."
Article Title: Low-density lipoprotein receptor-related protein 6 regulates cardiomyocyte-derived paracrine signaling to ameliorate cardiac fibrosis.
Journal: Theranostics
doi: 10.7150/thno.48787
Figure Legend Snippet: Figure 1. Cardiomyocyte-specific overexpression of LRP6 prevents cardiac dysfunction induced by pressure overload. (A), Echocardiographic analysis of fraction shortening (FS) in mice at different time-points (3d, 1w, 2w, and 4w) after TAC. *p < 0.05 vs Sham group; n = 6-10 mice/each group. (B), Western blot analysis of p-LRP6 and LRP6 levels in left ventricular tissues from mice at different time-points (3d, 1w, 2w, and 4w) after TAC. *p < 0.05; **p < 0.01 vs sham group; n = 4 mice/ each group. (C), Summary of the generation of tamoxifen-inducible cardiac-specific LRP6 overexpressing mice. (D), Representative images of Western blot analysis of LRP6 expression in heart and kidney tissues from LRP6CAG/MCM after injection of tamoxifen or DMSO for 3 consecutive days. (E), Representative images of Western blot analysis of LRP6 expression in isolated CMs and non-CMs from tamoxifen-injected LRP6CAG/MCM (LRP6 Over) or –MCM (MCM) mice. CMs: cardiomyocytes. (F), Overall strategy of exploring the effects of cardiac LRP6 overexpression in TAC mice. (G), Echocardiographic analysis of cardiac function in tamoxifen-injected LRP6CAG/MCM (LRP6 Over) or –MCM (MCM) mice at 2 weeks and 4 weeks after TAC or sham operation. FS: fraction shortening; EF: ejection fraction; LVID;d: left ventricular diastolic internal diameter. HR: heart rate; *p < 0.05; **p < 0.01; n = 7-12/each group.
Techniques Used: Over Expression, Western Blot, Expressing, Injection, Isolation
Figure Legend Snippet: Figure 2. Cardiomyocyte-specific overexpression of LRP6 attenuates cardiac hypertrophy and fibrosis induced by pressure overload. (A), HE and Masson staining of cross heart sections. Scale bars, 2 mm. (B), Representative images of Masson staining heart tissue were showed and the cardiac interstitial and vascular fibrosis were quantitatively analyzed. Scale bars, 100 um. (C), Western blot analysis of p-LRP6, LRP6, Col1, Col3, α-SMA, MMP2, MMP9, TGF-β1, p-smad2/3 in heart tissues. *p < 0.05; **p < 0.01; ***p<0.001; n = 3-5/each group. (D), Quantitative analysis of the ratio of heart weight/body weight (HW/BW) and heart/tibia (HW/TL). *p < 0.05; **p < 0.01; ***p < 0.001; n = 4-7/each group. Tamoxifen-injected-LRP6CAG/MCM (LRP6 Over) or –MCM (MCM) mice were analyzed at 4 weeks after TAC or sham operation.
Techniques Used: Over Expression, Staining, Western Blot, Injection
Figure Legend Snippet: Figure 3. Cardiomyocyte-specific overexpression of LRP6 inhibits the expression of cardiomyocyte-derived-Wnt5a/11 under pressure overload. (A), Western blot analysis of LRP6 expression in CMs, and Col1, MMP2, MMP9, TGF-β1, α-SMA, and p-smad2/3 expression in CFs. Stretched (MS) or control CMs were pre-transfected with LRP6 adenovirus (Ad-LRP6) or control adenovirus (Ad-CON), and the culture medium from these CMs was used to stimulate CFs. *p < 0.05; **p < 0.01; ***p < 0.001; n = 4/each group. (B), Western blot analysis of Wnt5a and Wnt11 expression in CMs and the culture medium. Stretched (MS) or control CMs were pre-transfected with LRP6 adenovirus (Ad-LRP6) or control adenovirus (Ad-CON). **p < 0.01; ***p < 0.001; n = 5-6/each group. (C), Western blot analysis of Wnt5a and Wnt11 expression in tamoxifen-injected-LRP6CAG/MCM (LRP6 Over) or –MCM (MCM) mice after TAC or sham operation. **p < 0.01; n = 5/each group.
Techniques Used: Over Expression, Expressing, Derivative Assay, Western Blot, Control, Transfection, Injection
Figure Legend Snippet: Figure 6. Cardiomyocyte-specific overexpression of LRP6 promotes the degradation of Wnt5a and Wnt11 by interaction with LRP6 and CTSD during pressure overload. (A), Western blot analysis of LRP6 and CTSD expression in tamoxifen-injected LRP6CAG/MCM (LRP6 Over) or –MCM (MCM) mice at 4 weeks after TAC or sham operation. *p < 0.05; **p < 0.01; n = 4 mice/each group. (B), Western blot analysis of LRP6 and CTSD expression in control (Ad-CON) or LRP6 overexpressing CMs (Ad-LRP6) with or without MS. ***p < 0.001; n = 4-6/each group. (C), Interaction of LRP6 and CTSD was analyzed by IP analysis in control (Ad-CON) or LRP6-overexpressing
Techniques Used: Over Expression, Western Blot, Expressing, Injection, Control
Figure Legend Snippet: Figure 9. Mutants of LRP6 or CTSD inhibit the interaction of LRP6 and CTSD. (A), Sequencing results of LRP6 and CTSD mutations. (B), Schematic diagram of LRP6 and CTSD showing approximate locations of the mutants. (C), IP analysis of the interaction among LRP6 WT, LRP6 (P1104S), or LRP6 (P1427Q) and CTSD WT or CTSD (G136R). LRP6 WT and CTSD WT or their mutant plasmids were transfected into 293T cells for 48 h. The experiment was repeated 4 times. (D), Western blot analysis of LRP6, CTSD, Wnt5a, Wnt11, and MESD in stretched COS7 cells transfected with LRP6 WT and CTSD WT or their mutant plasmids as in (C). ****P < 0.0001, n = 3/each group.
Techniques Used: Sequencing, Mutagenesis, Transfection, Western Blot
Figure Legend Snippet: Figure 10. Proposed model of cardiac protection mediated by cardiac-specific LRP6 overexpression in response to pressure overload. LRP6 overexpression suppresses β-catenin activation, which may contribute to the inhibition of cardiac hypertrophy. LRP6 overexpression inhibits cardiomyocyte-derived Wnt5a/Wnt11 to inhibit cardiac fibrosis. Cardiomyocyte-expressed LRP6 interacts with CTSD, which may promote the degradation of Wnt5a and Wnt11.
Techniques Used: Over Expression, Activation Assay, Inhibition, Derivative Assay
Related Articles
Sequencing:Article Title: Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3β. Article Snippet: .. The Article Title: Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3β Article Snippet: .. The Construct:Article Title: Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3β. Article Snippet: .. The Article Title: Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3β Article Snippet: .. The |
